Citadel Advisors’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-29,700
| Closed | -$5.11M | – | 15466 |
|
|
2021
Q3 | $5.11M | Buy |
29,700
+25,400
| +591% | +$3.32M | ﹤0.01% | 4256 |
|
|
2021
Q2 | $540K | Sell |
4,300
-2,800
| -39% | -$353K | ﹤0.01% | 9901 |
|
|
2021
Q1 | $963K | Sell |
7,100
-800
| -10% | -$103K | ﹤0.01% | 8215 |
|
|
2020
Q4 | $1.01M | Sell |
7,900
-3,300
| -29% | -$387K | ﹤0.01% | 6777 |
|
|
2020
Q3 | $1.26M | Sell |
11,200
-4,300
| -28% | -$428K | ﹤0.01% | 5609 |
|
|
2020
Q2 | $1.48M | Sell |
15,500
-19,400
| -56% | -$1.87M | ﹤0.01% | 5099 |
|
|
2020
Q1 | $3.14M | Buy |
34,900
+25,200
| +260% | +$1.96M | ﹤0.01% | 3391 |
|
|
2019
Q4 | $514K | Sell |
9,700
-3,200
| -25% | -$146K | ﹤0.01% | 6763 |
|
|
2019
Q3 | $510K | Sell |
12,900
-22,800
| -64% | -$989K | ﹤0.01% | 6713 |
|
|
2019
Q2 | $1.47M | Buy |
35,700
+13,900
| +64% | +$576K | ﹤0.01% | 5059 |
|
|
2019
Q1 | $1.01M | Buy |
21,800
+9,900
| +83% | +$435K | ﹤0.01% | 5558 |
|
|
2018
Q4 | $518K | Sell |
11,900
-21,700
| -65% | -$1.08M | ﹤0.01% | 6342 |
|
|
2018
Q3 | $1.92M | Sell |
33,600
-11,100
| -25% | -$545K | ﹤0.01% | 4483 |
|
|
2018
Q2 | $2.17M | Buy |
44,700
+32,800
| +276% | +$1.2M | ﹤0.01% | 3982 |
|
|
2018
Q1 | $465K | Buy |
+11,900
| New | +$506K | ﹤0.01% | 5999 |
|
|
2017
Q3 | – | Sell |
-9,500
| Closed | -$289K | – | 8266 |
|
|
2017
Q2 | $289K | Sell |
9,500
-5,500
| -37% | -$159K | ﹤0.01% | 5970 |
|
|
2017
Q1 | $397K | Buy |
+15,000
| New | +$395K | ﹤0.01% | 5426 |
|
|
2016
Q4 | – | Sell |
-7,900
| Closed | -$286K | – | 8079 |
|
|
2016
Q3 | $286K | Buy |
7,900
+1,800
| +30% | +$59.6K | ﹤0.01% | 5747 |
|
|
2016
Q2 | $207K | Sell |
6,100
-3,600
| -37% | -$117K | ﹤0.01% | 5789 |
|
|
2016
Q1 | $256K | Sell |
9,700
-3,500
| -27% | -$102K | ﹤0.01% | 5304 |
|
|
2015
Q4 | $644K | Buy |
13,200
+8,300
| +169% | +$299K | ﹤0.01% | 4145 |
|
|
2015
Q3 | $122K | Sell |
4,900
-15,400
| -76% | -$463K | ﹤0.01% | 6764 |
|
|
2015
Q2 | $642K | Buy |
20,300
+12,400
| +157% | +$400K | ﹤0.01% | 4585 |
|
|
2015
Q1 | $301K | Sell |
7,900
-6,300
| -44% | -$251K | ﹤0.01% | 5641 |
|
|
2014
Q4 | $553K | Buy |
14,200
+7,800
| +122% | +$272K | ﹤0.01% | 4593 |
|
|
2014
Q3 | $194K | Buy |
6,400
+4,500
| +237% | +$127K | ﹤0.01% | 5760 |
|
|
2014
Q2 | $65K | Buy |
+1,900
| New | +$63.5K | ﹤0.01% | 6559 |
|
Citadel Advisors's XLRN Position: Q4 2021 in Review
Citadel Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 23,399 shares — an estimated $4.03M sold.
Citadel Advisors first reported a position in XLRN in Q2 2014 and held it in 29 quarters. The position peaked at $51.8M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Citadel Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Citadel Advisors sold 23,399 Acceleron Pharma shares in Q4 2021, an estimated $4.03M.
- Citadel Advisors first reported a position in Acceleron Pharma in Q2 2014 and held it in 29 quarters.
- Citadel Advisors's Acceleron Pharma position peaked at $51.8M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.